Effect of phenytoin and levetiracetam on busulfan blood concentration in children undergoing hematopoietic stem cell transplantation

Shi-Xi XU, Guang-Ting ZENG, Jing-Yu WANG, Shu-Lan LIU, Jing LIU, Bo-Yan DENG, Ji-Ming LUO, Jie LIN, An-Fa WANG

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1378-1383.

PDF(604 KB)
HTML
PDF(604 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1378-1383. DOI: 10.7499/j.issn.1008-8830.2505129
CLINICAL RESEARCH

Effect of phenytoin and levetiracetam on busulfan blood concentration in children undergoing hematopoietic stem cell transplantation

Author information +
History +

Abstract

Objective To study the effect of prophylactic phenytoin (PHT) or levetiracetam (LEV) on busulfan (BU) blood concentration in children undergoing hematopoietic stem cell transplantation. Methods Pediatric patients conditioned with BU plus cyclophosphamide and fludarabine at the First People's Hospital of Chenzhou from September 2023 to February 2025 were retrospectively included. Patients were grouped by prophylactic antiepileptic regimen into PHT (n=24) and LEV (n=26). BU blood concentrations at the end of infusion (0 hour) and at 1, 2, and 4 hours post-infusion were compared between groups. Results At 0 hour post-infusion, BU blood concentrations did not differ significantly between groups (P>0.05). At 1, 2, and 4 hours post-infusion, BU blood concentrations were higher in the LEV group than in the PHT group (P<0.05). The area under the concentration-time curve from 0 to ∞ (AUC0-∞) was greater in the LEV group (P<0.001), and the attainment rate of AUC0-∞ was higher in the LEV group than in the PHT group (73% vs 21%, P<0.001). No significant differences were observed between groups in time to hematopoietic engraftment or in the incidence of BU-related adverse drug reactions (P>0.05). Conclusions Compared with PHT, LEV prophylaxis is associated with higher BU blood concentration and a higher AUC0-∞ attainment rate. There is no observed difference in BU efficacy or safety between PHT and LEV.

Key words

Busulfan / Phenytoin / Levetiracetam / Therapeutic drug monitoring / Drug interaction / Hematopoietic stem cell transplantation / Child

Cite this article

Download Citations
Shi-Xi XU , Guang-Ting ZENG , Jing-Yu WANG , et al . Effect of phenytoin and levetiracetam on busulfan blood concentration in children undergoing hematopoietic stem cell transplantation[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(11): 1378-1383 https://doi.org/10.7499/j.issn.1008-8830.2505129

References

[1]
冯安华, 施继敏, 傅华睿, 等. 异基因造血干细胞移植治疗Shwachman-Diamond综合征: 3例报告及文献复习[J]. 中华血液学杂志, 2024, 45(7): 689-693. PMCID: PMC11388119. DOI: 10.3760/cma.j.cn121090-20240107-00009 .
[2]
Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress[J]. Haematologica, 2020, 105(12): 2716-2729. PMCID: PMC7716373. DOI: 10.3324/haematol.2019.245688 .
[3]
Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis[J]. Blood Adv, 2020, 4(9): 1998-2010. PMCID: PMC7218427. DOI: 10.1182/bloodadvances.2020001748 .
[4]
张建华, 张傲利, 董春霞, 等. 应用改良BU/CY方案预处理联合自体外周血造血干细胞移植治疗青年中、低危急性髓系白血病疗效观察[J]. 中国实验血液学杂志, 2019, 27(2): 360-364. DOI: 10.19746/j.cnki.issn1009-2137.2019.02.008 .
[5]
Peters C, Dalle JH, Locatelli F, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study[J]. J Clin Oncol, 2021, 39(4): 295-307. PMCID: PMC8078415. DOI: 10.1200/JCO.20.02529 .
[6]
McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting[J]. Expert Opin Drug Metab Toxicol, 2009, 5(8): 957-969. DOI: 10.1517/17425250903107764 .
[7]
Domingos V, Nezvalova-Henriksen K, Dadkhah A, et al. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)[J]. Bone Marrow Transplant, 2024, 59(12): 1641-1653. DOI: 10.1038/s41409-024-02413-0 .
[8]
Seydoux C, Uppugunduri CRS, Medinger M, et al. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan[J]. Bone Marrow Transplant, 2023, 58(7): 811-816. PMCID: PMC10325946. DOI: 10.1038/s41409-023-01963-z .
[9]
Krivoy N, Hoffer E, Lurie Y, et al. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children[J]. Curr Drug Saf, 2008, 3(1): 60-66. DOI: 10.2174/157488608783333899 .
[10]
Marsit H, Philippe M, Neely M, et al. Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children[J]. Clin Pharmacokinet, 2020, 59(8): 1049-1061. DOI: 10.1007/s40262-020-00877-z .
[11]
U.S. Food and Drug Administration. Otsuka America Pharmaceutical, Inc. busulfan injection[EB/OL]. (2020-03)[2023-12].
[12]
夏凡, 刘明红, 于迪, 等. 静脉滴注白消安致急性精神异常[J]. 中国医院药学杂志, 2020, 40(17): 1902-1903. DOI: 10.13286/j.1001-5213.2020.17.21 .
[13]
Albert MH, Slatter MA, Gennery AR, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis[J]. Blood, 2022, 139(13): 2066-2079. DOI: 10.1182/blood.2021014687 .
[14]
Eberly AL, Anderson GD, Bubalo JS, et al. Optimal prevention of seizures induced by high-dose busulfan[J]. Pharmacotherapy, 2008, 28(12): 1502-1510. DOI: 10.1592/phco.28.12.1502 .
[15]
Nakashima T, Tanaka T, Koido K, et al. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation[J]. Int J Hematol, 2019, 109(6): 694-699. DOI: 10.1007/s12185-019-02637-7 .
[16]
Akiyama K, Kume T, Fukaya M, et al. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients[J]. Cancer Chemother Pharmacol, 2018, 82(4): 717-721. PMCID: PMC6132870. DOI: 10.1007/s00280-018-3659-8 .
[17]
Cucchiara F, Ferraro S, Luci G, et al. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: preclinical and clinical data[J]. Pharmacol Res, 2022, 175: 105976. DOI: 10.1016/j.phrs.2021.105976 .
[18]
Díaz-Carrasco MS, Sánchez-Salinas A, Fernández-Ávila JJ, et al. Prospective observational study of oral clonazepam to prevent high-dose busulfan-induced seizures in adult patients[J]. J Egypt Natl Canc Inst, 2025, 37(1): 4. DOI: 10.1186/s43046-025-00257-3 .
[19]
Hamidieh AA, Hamedani R, Hadjibabaie M, et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study[J]. Pediatr Hematol Oncol, 2010, 27(7): 529-533. DOI: 10.3109/08880018.2010.496895 .
[20]
Tsujimoto SI, Shirai R, Utano T, et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation[J]. Int J Hematol, 2020, 111(3): 463-466. DOI: 10.1007/s12185-019-02795-8 .
[21]
王磊, 李梦, 张建平, 等. 白消安为主的不同预处理方案在异基因造血干细胞移植中应用的短期疗效和安全性[J]. 中国新药与临床杂志, 2022, 41(6): 357-362. DOI: 10.14109/j.cnki.xyylc.2022.06.08 .
[22]
中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31(4): 355-384. DOI: 10.3760/cma.j.cn501113-20230419-00176-1 .
[23]
王伊娜, 左力, 燕宇. 《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》解读(三):抗肿瘤药物治疗患者的肾功能评估(第2部分)[J]. 药物不良反应杂志, 2024, 26(7): 385-389. DOI: 10.3760/cma.j.cn114015-20240507-00308 .
[24]
冯新颖, 吴云娇, 李佳朋, 等. 白消安个体化给药的群体药代动力学研究现状[J]. 中国临床药理学杂志, 2018, 34(24): 2884-2888. DOI: 10.13699/j.cnki.1001-6821.2018.24.023 .
[25]
Lawson R, Staatz CE, Fraser CJ, et al. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients[J]. Clin Pharmacokinet, 2021, 60(1): 17-51. DOI: 10.1007/s40262-020-00947-2 .
[26]
Abbasi N, Vadnais B, Knutson JA, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients[J]. J Clin Pharmacol, 2011, 51(10): 1429-1438. PMCID: PMC3117932. DOI: 10.1177/0091270010382915 .
[27]
Nguyen AH, Biswas M, Puangpetch A, et al. Effect of GSTA1 variants on busulfan-based conditioning regimen prior to allogenic hematopoietic stem-cell transplantation in pediatric Asians[J]. Pharmaceutics, 2022, 14(2): 401. PMCID: PMC8880478. DOI: 10.3390/pharmaceutics14020401 .
[28]
Feng X, Wu Y, Zhang J, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis[J]. BMC Pediatr, 2020, 20(1): 176. PMCID: PMC7168843. DOI: 10.1186/s12887-020-02028-6 .
[29]
Sandström M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients[J]. Bone Marrow Transplant, 2001, 28(7): 657-664. DOI: 10.1038/sj.bmt.1703229 .
[30]
Chaguaceda C, Aguilera-Jiménez V, Gutierrez G, et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant[J]. Int J Clin Pharm, 2020, 42(2): 351-354. DOI: 10.1007/s11096-020-00977-7 .

Footnotes

所有作者均声明不存在利益冲突。

PDF(604 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/